Fundraising FoxHealthspan Capital — Full Portfolio
5 tracked investments · listed companies and verified rows first
Fauna Bio applies AI and computational analysis to its proprietary biobank of data from extreme mammals such as hibernating species to identify drug targets that are conserved across species including humans.
AI & Machine LearningBiotechDeep TechHealthtechEmeryville, US
Linda Goodman(Founder)inAshley(CEO)
Co-investorsage1Farvatn VentureGRIDS CapitalLifeforce CapitalMetaplanetPalo Santo VC+4 more
ImmuneBridge is a company working in cell-based cancer immunotherapy, including research on engineered natural killer cells for solid tumor treatment.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesSan Francisco, US
Peretz Partensky(Executive Officer, Director)inStuart Alexander Jacobson(Executive Officer, Director)Nina Horowitz(Chief Executive Officer)inRui Tostoes(Chief Technology Officer)inAlicia Jackson(Director)in
BoardDylan Morris(Director)in
Co-investorsM VenturesNFXGaingelsInsight PartnersOne Way VenturesSand Hill Angels
__Twitter.png)
Modulate Bio develops small-molecule GABAA positive allosteric modulators to treat neurological disorders including Essential Tremor, epilepsy, and anxiety.
BiotechDeep TechHealthtechAllston, US
Dario Doller(Co-founder)inKevin Hodgetts(Founding Lab / Co-founder)inAndrew Thomson(Executive Officer, Director, Promoter)in
Co-investorsPillar VCPalo Santo VC
Oisín Biotechnologies develops non-viral genetic therapies built on its Fusogenix Proteo-Lipid Vehicle (PLV) delivery platform, which delivers DNA and RNA payloads to tissues throughout the body and allows repeat dosing.
BiotechHealthtechLongevitySeattle, US
Matthew Scholz(Executive Officer, Director)inEric Garcia(Executive Officer)inStephen Hilbert(Executive Officer)John Lewis(Executive Officer)inGary Hudson(Executive Officer, Director)in
BoardDavid Gobel(Director)
Co-investorsIKJ Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Jung+ Longevity
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.